Clostridium butyricum as Next Generation Probiotics
Background Gastrointestinal Disorders Metabolic Disease Cancer Therapy Products FAQs Resources
Introduction of Clostridium butyricum
Creative Biolabs has been a long-term expert in the field of next-generation probiotics (NGPs). Based on our deep understanding of Clostridium butyricum, our scientists will build up best-fit solutions to develop C. butyricum as probiotics for our global customers' specific requirements.
Introduction of Clostridium butyricum
Clostridium butyricum is obligate anaerobic, Gram-positive, spore-forming rod bacterium. Cells are rod-shaped, motile, and peritrichously flagellated. C. butyricum is named for its capacity to produce high amounts of butyric acid. Several strains of C. butyricum have been described in a variety of environments and are common human and animal gut commensal bacteria. C. butyricum is found in the feces of 10-20% of healthy humans. They are important bioproduction microbial genus bacteria, and non-toxigenic strains present potential as the probiotics.
Studies on intestinal flora have identified certain bacteria that are beneficial to the body, which can exhibit a positive effect on the host and serve as a probiotic. C. butyricum is a spore-like micro-ecological preparation. C. butyricum produces butyric acid, the preferred energy source for intestinal epithelial cells, and promotes the proliferation of Bifidobacteria and Lactobacilli. It decreases chemotherapy-induced diarrhea, reduces the systemic inflammatory response, and helps to maintain the condition of the intestinal flora. C. butyricum administration is a safe and effective treatment for chemotherapy-induced diarrhea in patients with lung cancer.
The pathogen C. difficile is responsible for a large proportion of antibiotic-associated diarrhea and colitis. C. butyricum MIYAIRI 588 (CBM588) produces large quantities of short-chain fatty acids (SCFA), especially butyrate, an active bacteriocin and sporulates, allowing it to resist antibiotics that may disrupt other gut flora. CBM588 has previously shown effectiveness against C. difficile in vivo and accordingly, and toxicity of C. difficile in vitro is greatly decreased. This derivative can be safely administered orally to humans and animals, as C. butyricum CBM588 has been safely used as a probiotic for many years.
C. butyricum CBM588 spores grow in the intestinal tract and produce SCFAs. CBM588 produced SCFAs may be carried into the liver, where they may improve lipid accumulation. In conclusion, CBM588 intake improves the accumulation of lipid droplets in livers against high-fat diet-induced NAFLD.
Clostridium, an obligate anaerobe, could regress tumors in mice. The nonpathogenic strain of C. butyricum M-55, which is proved to be safe by self-injecting the bacterium, can lead to the destruction of large parts of the tumor. Administration of C. butyricum M-55 results in the restricted colonization of the tumor and produces extensive oncolysis after injection. These results are confirmed that the ability of C. butyricum M55 to colonize tumors selectively has allowed them to be used as delivery vectors in mouse tumor models, without severe immune responses or toxic side effects. Thanks to these properties, the strain is named C. oncolyticum and later reclassified as C. sporogenes M-55.
As a pioneer and undisputed global leader in the field of NGPs, Creative Biolabs is professional in applying advanced strategies to satisfy various project demands. If there are any questions, please feel free to contact us for more detailed information.
Related Products
|
CAT
|
Product Name
|
Product Overview
|
|
LBST-061FG
|
Clostridium butyricum; 19398
|
Clostridium butyricum is a strictly anaerobic endospore-forming Gram-positive butyric acid–producing bacillus.
|
|
LBST-062FG
|
Clostridium butyricum; 1.2756
|
Clostridium butyricum was isolated from activated sludge. It is a strictly anaerobic endospore-forming Gram-positive butyric acid–producing bacillus.
|
|
LBST-063FG
|
Clostridium butyricum; 185375
|
Clostridium butyricum is a strictly anaerobic endospore-forming Gram-positive butyric acid-producing bacillus.
|
FAQs
What are the key characteristics of Clostridium butyricum that make it suitable as a next-generation probiotic?
Clostridium butyricum is a Gram-positive, spore-forming anaerobic bacterium that produces butyric acid. This acid is vital for the health of intestinal cells and supports the growth of beneficial gut bacteria such as Bifidobacteria and Lactobacilli. It's recognized for its ability to enhance intestinal health and support the immune system.
What is the safety profile of Clostridium butyricum as a probiotic?
Clostridium butyricum has a long history of safe use in various therapeutic applications. It is non-toxigenic and has been effectively used to manage conditions such as Clostridium difficile infections by outcompeting harmful bacteria and restoring gut flora balance.
What innovative technologies are used in the discovery of Clostridium butyricum strains?
The discovery of Clostridium butyricum strains involves advanced genomic and phenotypic methods, such as metagenomics, metatranscriptomics, and microbial identification techniques, ensuring the selection of strains with optimal therapeutic potential.
What support does the service provide for scaling up Clostridium butyricum probiotics?
The service offers comprehensive scale-up support, from lab-scale production to GMP-compliant manufacturing, ensuring that probiotic products meet stringent quality standards necessary for clinical and therapeutic applications.
Resources
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
Related Services
